Dopamine replacement therapy in PD, and acetylcholine esterase (AChE) inhibitors in AD, were milestones in the symptomatic therapy of these diseases; nevertheless, they are insufficient to prevent or stop the chronic progression of neurodegeneration [11,12]. This evidence concerns the gene ACHE and Parkinson disease.